Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
Purpose: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who recei...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Particle Therapy Co-operative Group
2021-10-01
|
| Series: | International Journal of Particle Therapy |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.14338/IJPT-21-00016 |
| _version_ | 1797203690969366528 |
|---|---|
| author | Alicia Bao, BS Andrew R. Barsky, MD Russell Maxwell, MD Justin E. Bekelman, MD Stefan Both, PhD John P. Christodouleas, MD, MPH Curtiland Deville, Jr, MD Penny Fang, MD Zelig A. Tochner, MD Neha Vapiwala, MD |
| author_facet | Alicia Bao, BS Andrew R. Barsky, MD Russell Maxwell, MD Justin E. Bekelman, MD Stefan Both, PhD John P. Christodouleas, MD, MPH Curtiland Deville, Jr, MD Penny Fang, MD Zelig A. Tochner, MD Neha Vapiwala, MD |
| author_sort | Alicia Bao, BS |
| collection | DOAJ |
| description | Purpose: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment.
Methods: One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS.
Results: The median length of follow-up was 8.3 years (range, 1.2–10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P >.05).
Conclusion: Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies. |
| first_indexed | 2024-04-24T08:23:21Z |
| format | Article |
| id | doaj.art-34367994553a4acab1273903c7300955 |
| institution | Directory Open Access Journal |
| issn | 2331-5180 |
| language | English |
| last_indexed | 2024-04-24T08:23:21Z |
| publishDate | 2021-10-01 |
| publisher | Particle Therapy Co-operative Group |
| record_format | Article |
| series | International Journal of Particle Therapy |
| spelling | doaj.art-34367994553a4acab1273903c73009552024-04-16T23:33:42ZengParticle Therapy Co-operative GroupInternational Journal of Particle Therapy2331-51802021-10-0184142410.14338/IJPT-21-00016i2331-5180-8-4-14Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam TherapyAlicia Bao, BS0Andrew R. Barsky, MD1Russell Maxwell, MD2Justin E. Bekelman, MD3Stefan Both, PhD4John P. Christodouleas, MD, MPH5Curtiland Deville, Jr, MD6Penny Fang, MD7Zelig A. Tochner, MD8Neha Vapiwala, MD91 Ohio State College of Medicine, The Ohio State University, Columbus, OH, USA2 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA2 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA2 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA3 Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands2 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA4 Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD, USA5 Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA2 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA2 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USAPurpose: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment. Methods: One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS. Results: The median length of follow-up was 8.3 years (range, 1.2–10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P >.05). Conclusion: Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies.https://theijpt.org/doi/pdf/10.14338/IJPT-21-00016prostate cancerradiotherapyproton beam therapy |
| spellingShingle | Alicia Bao, BS Andrew R. Barsky, MD Russell Maxwell, MD Justin E. Bekelman, MD Stefan Both, PhD John P. Christodouleas, MD, MPH Curtiland Deville, Jr, MD Penny Fang, MD Zelig A. Tochner, MD Neha Vapiwala, MD Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy International Journal of Particle Therapy prostate cancer radiotherapy proton beam therapy |
| title | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
| title_full | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
| title_fullStr | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
| title_full_unstemmed | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
| title_short | Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy |
| title_sort | long term clinical outcomes in favorable risk prostate cancer patients receiving proton beam therapy |
| topic | prostate cancer radiotherapy proton beam therapy |
| url | https://theijpt.org/doi/pdf/10.14338/IJPT-21-00016 |
| work_keys_str_mv | AT aliciabaobs longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT andrewrbarskymd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT russellmaxwellmd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT justinebekelmanmd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT stefanbothphd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT johnpchristodouleasmdmph longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT curtilanddevillejrmd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT pennyfangmd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT zeligatochnermd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy AT nehavapiwalamd longtermclinicaloutcomesinfavorableriskprostatecancerpatientsreceivingprotonbeamtherapy |